Wegovy (semaglutide) weight loss support

Please click the following link:- https://www.wegovy.co.uk/patientresources.html

Our holistic medicated weight loss support not only provides the medication to suppress your appetite but lots of tools to get you to your goal weight and help you maintain it.

We will provide you with delicious healthy recipes every month to inspire you to eat fewer calories to get you to your goal weight.

Our fitness coach Gemma has designed a programme of easy exercises that you can do in the comfort of your own home to get you moving and increase your metabolism. This will result in you getting fitter and leaner.

We will advise you on recommended daily water consumption to aid your weight loss.

Tips and advice on how to achieve the best possible nights sleep.

We understand that losing weight is not a simple process and involves getting your mind into the right gear! Therefore, we will suggest a mindfulness App to help you with stress management.

Wegovy is the first prescription weight-loss medication offering once-weekly dosing.

Wegovy contains the active ingredient Semaglutide.

wegovy™ UK is for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems to help them lose weight and keep it off. wegovy™ should be used with a reduced-calorie meal plan and increased physical activity.

Wegovy™ UK works by mimicking a hormone that targets areas of the brain involved in regulating appetite and food intake. This can help you eat less, which leads to WEIGHT LOSS. It also delays the time it takes for your stomach to empty and so you feel fuller for longer.

In a 68-week medical study of 1,961 adults living with obesity or excess weight with a related medical problem:-

ADULTS LOST ON AVERAGE 35 pounds (16kg) or about 15% of their body weight!

while taking wegovy™

• People taking placebo lost an average of 6 lbs (or ~2.4% body weight)

• The average starting weight for both groups was ~232 lbs

  In the STEP clinical trials wegovy® patients started to lose weight as early as week 4

  Most importantly, while taking wegovy™, people not only lost weight, but also kept it off!

You should inject once a week, any time of the day, with or without food. You might find it helpful to get into a routine, like taking Wegovy® on a Sunday just before bed.

The wegovy starting dose is 0.25 mg subcutaneously, SC, on the same day each week for4 weeks.

You should increase the dose as indicated every 4 weeks until the full maintenance dose of 2.4 mg is reached.

By the start of the fifth month you should be on the maximum maintenance dose.

1-4 weeks ı 0.25 mg SC once a week, on the same day each week, for 4 weeks

5-8 weeks ı 0.5 mg SC once a week for 4 weeks

9-12 weeks ı 1.0 mg SC once weekly for 4 weeks

13-16 weeks ı 1.7 mg SC once weekly for 4 weeks

Week 17 onwards ı 2.4 mg SC once a week on the same day each week

Each package contains one package leaflet, one Wegovy® pen of one of 5 strengths, 0,25mg, 0.5mg, 1mg, 1.7mg, 2.4mg and 4 needles.

Your pen is to be used once a week for 4 weeks. The pack includes:

• Wegovy FlexTouch pen

• 4 NovoFine Plus needles

• Leaflet

Choose an injection site in one of the body areas indicated below. You can choose your upper arms, upper legs or stomach (keep a 5 cm distance from your belly button). You may inject in the same body area each week, but make sure it is not in the same spot as used the last time.

Insert the needle into your skin. Make sure you can see the dose counter and do not cover it with your fingers as this could interrupt the injection.

Press and hold down the dose button until the dose counter shows -0- . Keep pressing the dose button with the needle in your skin and slowly count to 6. The -0-must line up with the dose pointer. You may hear or feel a click when the dose counter returns to -0- .

• If a dose is missed, it should be administered as soon as possible and within 5 days after the missed dose.
• If more than 5 days have passed, the missed dose should be skipped, and the next dose should be administered on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
• If more doses are missed, reducing the starting dose for re-initiation should be considered. Please call us on 0161 491 1899 for advice.

The day of weekly administration can be changed if necessary as long as the time between two doses is at least 3 days (>72 hours). After selecting a new dosing day, once-weekly dosing should be continued.

The wegovy pen comes with the needles already in the box with the pen. There are 4 NovoFine Plus needles with each strength of pen.

Your pen is designed to be used with NovoFine Plus, NovoFine or NovoTwist disposable needles up to a length of 8 mm.

• Before opening: Store in a refrigerator (2°C to 8°C). Keep away from the cooling element.
• Do not freeze your pens and do not use it if it has been frozen.
• Do not use this medicine after the expiry date which is stated on the pen label and carton after ‘EXP’. The expiry date refers to the last day of that month.
• Keep the pen cap on in order to protect from light.
• During use: You can keep the pen for 6 weeks when stored at a temperature below 30°C or in a refrigerator (2°C to 8°C).

Very common: may affect more than 1 in 10 people

• headache

• feeling sick (nausea)

• being sick (vomiting)

• diarrhoea

• constipation

• stomach pain.

• feeling weak or tired – these usually go away over time.

Common: may affect up to 1 in 10 people

• feeling dizzy

• upset stomach or indigestion

• burping

• gas (flatulence)

• bloating of the stomach

• inflamed stomach (‘gastritis’) – the signs include stomach ache, feeling sick (nausea) or being sick (vomiting)

• reflux or heartburn – also called ‘gastrooesophageal reflux disease’

• gallstones

• hair loss

• injection site reactions

• low blood sugar (hypoglycaemia) in patients with diabetes.

For a full list please download the patient information leaflet

• As there is limited therapeutic experience in patients 75 years of age or over, use in these patients is not recommended

• Anyone with liver or kidney disease should not take wegovy(semaglutide)

• Hypersensitivity to semaglutide or to any of the excipients listed in the patient information leaflet.

• This medicine is not recommended if you have a severe stomach or gut problem which results in delayed stomach emptying (called gastroparesis), or if you have an inflammatory bowel disease.

• Semaglutide should be used with caution in patients with thyroid disease.

• Upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives more frequent monitoring of International Normalised Ratio (INR) is recommended.

• Severe heart failure or ever had a stroke

• Disease of the pancreas

• Pregnancy and breast-feeding:- This medicine should not be used during pregnancy, as it is not known if it may affect your unborn child. Therefore, it is recommended to use contraception while using this medicine. If you wish to become pregnant, you should stop using this medicine at least two months in advance. If you become or are pregnant, think you may be pregnant or are planning to have a baby when using this medicine, talk to your doctor straight away, as your treatment will need to be stopped. Do not use this medicine if you are breast-feeding, as it is unknown if it passes into breast milk.

Novo Nordisk, the manufacturer, recommend that Wegovy should be discontinued at least 2 months before a planned pregnancy.

Adults taking wegovy™ experienced improvements in blood pressure, cholesterol and blood sugar. Thus improving their overall cardiovascular health.

Patient Information Leaflet